What this study is
Continuous glucose monitor (CGM) technology has become increasingly prevalent in the population and has the ability to transform care of patients living with prediabetes. While the technology was initially utilized primarily by patients living with type 1 diabetes using insulin pump therapy, it has become more widely used as part of care in patients living with type 1 or 2 diabetes on any kind of insulin therapy.
What's being tested
- Stelo CGM
Intervention · DEVICE
The Stelo Glucose Biosensor is built on the most accurate continuous glucose monitoring technology from Dexcom and is simple and painless to apply. By sending glucose levels directly to your smartphone,* it gives you just the right amount of information to work with.
Study details
- Official title
- Trial of Continuous Glucose Monitoring (CGM) Technology in Persons Living With Prediabetes
- Sponsor
- Wake Forest University Health Sciences
- Conditions
- Prediabetes
- Enrolling
- 100 people
- Starts
- 2027-04
- Est. completion
- 2027-11
- Design
- Open-label, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Subjects affiliated with one of the two institutional ambulatory clinics participating in this study who are meeting criteria for prediabetes listed on American Diabetes Association website, which includes A1c = or > than 5.7% and < or = 6.4%, who also have reliable access to a smartphone device compatible with the CGM application
- Greater than or equal to 18 years old
You can't join if
- Subjects who have been diagnosed with type 1 or type 2 diabetes mellitus, as defined as A1c > or = 6.5%
- Subjects who do not have reliable access to a smartphone device compatible with the CGM application
- Pregnant patients
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openWake Forest University Health Sciences
Winston-Salem, North Carolina, United States
- Meghan Willoughby, MD · Contact317-938-5421meghan.willoughby@advocatehealth.org
- Catherine Price, MD · Contact912-682-0558Catherine.Price@wfusm.edu
Study team
Sponsor
Wake Forest University Health Sciences
Study ID IRB00143795
Principal investigator
Catherine Price, MD
Wake Forest University Health Sciences
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.